iBio
IBIO | NASDAQ
$0.71
-$0.02 (-2.97%)
At close: Nov 16, 2026, 4:00 PM ET
$0.69
-$0.02 (-2.11%)
After-hours:
Nov 16, 2026, 7:55 PM ET
-2.97%
(1D)No price chart data available for 1D timeframe.
Rating
41.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #490/1021 (Top 48%)
Key Statistics
Market Data
Market Cap $107.62M
1D Range
0.68 0.77
52W Range
0.68 3.07
Valuation (TTM)
PE -2.54
PB 1.37
EV/EBITDA -0.97
Valuation (NTM)
Forward PE N/A
Forward PEG 3.78
Price Target $5.00
Cash Flow
FCF Yield -25.6%
SBC Adj. FCF Yield -27.0%
SBC Impact -5.4%
Margins
Gross Margin 54.3%
Operating Margin -3025.6%
FCF Margin -2566.3%
Growth (CAGR)
Revenue 3Y | 5Y 178.1% |
-12.1%
Dil EPS 3Y | 5Y 114.8% |
95.4%
FCF 3Y | 5Y -25.3% |
20.6%
Returns
ROA -39.3%
ROE -46.8%
ROIC -40.3%
Financial Health
Net Cash
$76.65M
Current Ratio 9.48
Interest Coverage -516.27
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two ...
Sector Healthcare
Industry Biotechnology
Employees 23
IPO Date Aug 19, 2008
Website www.ibioinc.com
Fiscal Year July - June
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.05
Beat +28.57%
YoY:
+54.55% REV
$1.1M
Beat +4300.00%
YoY:
+1000.00%Next Earnings
Feb 9, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$5.00
Upside
+604.23%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove IBIO